In our study, we found that (a) PTPRH exhibits recurrent ASE in neuroblastoma, (b) low expression of PTPRH is associated with adverse patient outcomes, and (c) knockdown of PTPRH increases proliferation and wound healing in neuroblastoma cell lines. This evidence concerns the gene PTPRH and neuroblastoma.